ATE210977T1 - Pharmazeutische zusammensetzung enthaltend ein alkanoyl-l-carnitin in kombination mit einer polyungesättigten fettsäure der omega-3-serie zur verhütung und behandlung von störungen des fettstoffwechsels - Google Patents

Pharmazeutische zusammensetzung enthaltend ein alkanoyl-l-carnitin in kombination mit einer polyungesättigten fettsäure der omega-3-serie zur verhütung und behandlung von störungen des fettstoffwechsels

Info

Publication number
ATE210977T1
ATE210977T1 AT96118681T AT96118681T ATE210977T1 AT E210977 T1 ATE210977 T1 AT E210977T1 AT 96118681 T AT96118681 T AT 96118681T AT 96118681 T AT96118681 T AT 96118681T AT E210977 T1 ATE210977 T1 AT E210977T1
Authority
AT
Austria
Prior art keywords
carnitine
disorders
alkanoyl
omega
prevention
Prior art date
Application number
AT96118681T
Other languages
English (en)
Inventor
Menotti Calvani
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Application granted granted Critical
Publication of ATE210977T1 publication Critical patent/ATE210977T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT96118681T 1995-12-21 1996-11-21 Pharmazeutische zusammensetzung enthaltend ein alkanoyl-l-carnitin in kombination mit einer polyungesättigten fettsäure der omega-3-serie zur verhütung und behandlung von störungen des fettstoffwechsels ATE210977T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000835A IT1277953B1 (it) 1995-12-21 1995-12-21 Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per

Publications (1)

Publication Number Publication Date
ATE210977T1 true ATE210977T1 (de) 2002-01-15

Family

ID=11403724

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96118681T ATE210977T1 (de) 1995-12-21 1996-11-21 Pharmazeutische zusammensetzung enthaltend ein alkanoyl-l-carnitin in kombination mit einer polyungesättigten fettsäure der omega-3-serie zur verhütung und behandlung von störungen des fettstoffwechsels

Country Status (13)

Country Link
US (1) US5753703A (de)
EP (1) EP0780124B1 (de)
JP (1) JPH09176005A (de)
KR (1) KR970032853A (de)
AT (1) ATE210977T1 (de)
CA (1) CA2191645C (de)
DE (1) DE69618158T2 (de)
DK (1) DK0780124T3 (de)
ES (1) ES2169197T3 (de)
IT (1) IT1277953B1 (de)
PT (1) PT780124E (de)
TW (1) TW522013B (de)
ZA (1) ZA9610769B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168104A (zh) * 1995-01-18 1997-12-17 大正制药株式会社 皮肤炎治疗剂
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6403124B1 (en) 1997-04-16 2002-06-11 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6482585B2 (en) * 1997-04-16 2002-11-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
US5863940A (en) 1997-12-01 1999-01-26 Sigma-Tau Healthscience S.P.A. Medicament and therapeutical method for treating idiopathic asthenozoospermia
US20020002154A1 (en) * 1998-02-11 2002-01-03 Pol-Henri Guivarc'h Method and composition for treatment of inflammatory conditions
EP0951909B2 (de) 1998-03-19 2010-10-20 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Kombinierte Zusammensetzung bestehend aus L-Karnitin oder L-Alkanoylkarnitin, einem Glycosaminoglycan und/oder einem seiner Bestandteile
IT1299161B1 (it) * 1998-04-17 2000-02-29 Sigma Tau Healthscience Spa Composizione comprendente l-carnitina o un'alcanoil l-carnitina e nadh e/o nadph
IT1302125B1 (it) * 1998-08-03 2000-07-31 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
IT1305308B1 (it) * 1999-03-26 2001-05-04 Biosint S P A Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione
IT1317008B1 (it) * 2000-04-04 2003-05-26 Sigma Tau Healthscience Spa Integratore alimentare energizzante sulla muscolatura scheletrica eprotettivo sull'apparato cardiovascolare.
US8252309B2 (en) * 2000-04-04 2012-08-28 Sigma-Tau Industrie Farmaceutiche Riunite Spa Dietary supplement energy-providing to skeletal muscles
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
WO2003009854A1 (en) * 2001-07-20 2003-02-06 Lonza Ag Lipid lowering composition comprising carnitine and phytosterol
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ES2208131B1 (es) * 2002-03-27 2005-09-01 Volker Bartz Metodo para la fabricacion de un medicamento reductor de niveles de lipidos en sangre para la administracion oral.
EP1466597A1 (de) * 2003-04-07 2004-10-13 Clinigenetics Verwendung von dha-Esteren in der Behandlung kardiovasculärer Krankheiten
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
AU2006268787B2 (en) * 2005-07-08 2012-02-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of a combination comprising L-carnitine or alkanoyl L-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
EP2777701A1 (de) * 2006-05-31 2014-09-17 Mochida Pharmaceutical Co., Ltd. Zusammensetzung zur Vermeidung des Auftretens von kardiovaskulären Ereignissen bei Patienten mit mehreren Risiken enthaltend den Ethylester der all-cis-5,8,11,14,17-Icosapentaensäure
WO2008093848A1 (ja) * 2007-02-02 2008-08-07 Sunstar Inc. ホスファチジルコリンを含有する炎症マーカー低減組成物
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
JP5563573B2 (ja) 2008-08-07 2014-07-30 エッセピア ソシエタ’ プロドッティ アンティビオティチ ソシエタ ペル アチオニ 症候性心不全の長期治療
US20110217252A1 (en) * 2008-11-11 2011-09-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
EP2355812B1 (de) * 2008-11-14 2019-07-10 Bomi P. Framroze Senkung des spiegels eines zirkulierenden oxidierten lipoprotein-beta-2-glycoprotein 1-komplexes von geringer dichte zur behandlung von arteriosklerose
JP2012514596A (ja) * 2009-01-05 2012-06-28 カラナス エーエス バイオオイル組成物、上記オイル組成物を含む製剤と、循環器疾患の予防又は治療のためのその使用
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
US20120136053A1 (en) * 2009-06-12 2012-05-31 Calanus As Copepod oil composition, formulations comprising the oil composition, and the use thereof to reduce accumulation of visceral fat, improve glucose tolerance, and prevent or treat obesity related diseases and disorders
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
US9125903B2 (en) * 2011-05-03 2015-09-08 Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. Composition useful for the treatment of lipid metabolism disorders
WO2013031729A1 (ja) * 2011-08-26 2013-03-07 国立大学法人大阪大学 糖尿病性心血管合併症の予防・治療剤
GB201223370D0 (en) 2012-12-24 2013-02-06 Univ Tartu Method of treatment using lactobacillus fermentum ME-3
WO2015069215A1 (en) * 2013-11-05 2015-05-14 Hill's Pet Nutrition, Inc. Methods and compositions for improving kidney function
WO2019038764A1 (en) * 2017-08-23 2019-02-28 Gavish-Galilee Bio Applications Ltd. COMPOSITIONS AND METHODS FOR TREATING AEROSCLASTER CARDIOVASCULAR DISEASE

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56115736A (en) * 1980-02-19 1981-09-11 Kagakuhin Kensa Kyokai Separation and purification of eicosapentaenoic acid and docosahexaenoic acid
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
WO1988001861A1 (en) * 1986-09-17 1988-03-24 Baxter Travenol Laboratories, Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic, vascular, cardiovascular, and/or thrombotic diseases
US4918104A (en) * 1987-06-16 1990-04-17 Weiss Howard S Method and composition for increasing the concentration of omega-3 polyunsaturated fatty acids in poultry and poultry eggs and poultry and eggs resulting therefrom
DE3726299A1 (de) * 1987-06-26 1989-02-23 Dietl Hans Fettemulsion zur intravenoesen anwendung
JP2839276B2 (ja) * 1989-01-23 1998-12-16 日本分光工業株式会社 超臨界流体抽出・分離方法及び装置
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
JPH0394655A (ja) * 1989-09-06 1991-04-19 Otsuka Pharmaceut Co Ltd 栄養補給用組成物
DE4012894C2 (de) * 1990-04-23 1998-11-12 Werner Dr Gielsdorf Pharmazeutisches Mittel zur Behandlung von Störungen des Fettstoffwechsels
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1254331B (it) * 1992-04-23 1995-09-14 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.
GB9214247D0 (en) * 1992-07-04 1992-08-19 Stephan Peter M Composition for use as a food or food supplement
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1256705B (it) * 1992-12-21 1995-12-12 Sigma Tau Ind Farmaceuti Procedimento per la preparazione di l-(-)-carnitina a partire da un prodotto di scarto avente opposta configurazione.

Also Published As

Publication number Publication date
DE69618158D1 (de) 2002-01-31
DK0780124T3 (da) 2002-04-15
EP0780124B1 (de) 2001-12-19
ES2169197T3 (es) 2002-07-01
CA2191645A1 (en) 1997-06-22
TW522013B (en) 2003-03-01
ITRM950835A1 (it) 1997-06-21
JPH09176005A (ja) 1997-07-08
KR970032853A (ko) 1997-07-22
CA2191645C (en) 2007-07-31
PT780124E (pt) 2002-06-28
DE69618158T2 (de) 2002-07-18
US5753703A (en) 1998-05-19
ZA9610769B (en) 1997-07-09
ITRM950835A0 (de) 1995-12-21
EP0780124A1 (de) 1997-06-25
IT1277953B1 (it) 1997-11-12

Similar Documents

Publication Publication Date Title
DE69618158D1 (de) Pharmazeutische Zusammensetzung enthaltend ein Alkanoyl-L-Carnitin in Kombination mit einer polyungesättigten Fettsäure der Omega-3-Serie zur Verhütung und Behandlung von Störungen des Fettstoffwechsels
DE69720787D1 (de) Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
DE69629273D1 (de) Zusammensetzungen enthaltend Propionyl-L-Carnitine und Hydroxyzitronensäure oder Pantothensäure
ATE43242T1 (de) Pharmazeutische oder diaetetische zusammensetzung mit hoher antithrombotischer und antiarteriosklerotischer wirkung.
DE60000133D1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
DE69624768T2 (de) Ernährungszusammensetzung
DE69409969D1 (de) Salze der mehrfach ungesättigten fettsäuren und diese enthaltende pharmazeutischen zusammensetzungen
NO940277L (no) Triglycerider og blandinger av slike
ES2119871T3 (es) Composiciones que contienen esteres de colesterilo y acidos grasos insaturados.
AU9137091A (en) Gaba and l-glutamic acid analogs for antiseizure treatment
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
HK37694A (en) Fatty acids compositions
CA2147302A1 (en) A lipid composition for normalizing injury
ATE11014T1 (de) Pharmazeutische und diaetetische zusammensetzung zur erhoehung der serie-l-pg-produktion.
ATE212194T1 (de) Nahrungsprodukt zur behandlung der ulzerativen kolitis sowie verwendung desselben
FI950909A (fi) Rasvahappojohdannaisia
IL121268A0 (en) Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
DE69826674D1 (de) Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend
ATE74762T1 (de) Pharmazeutisches praeparat zur behandlung von stoerungen des fettstoffwechsels (hyperlipoproteinaemien).
ES2037265T3 (es) Nuevo aceite dietetico.
ITRM920165A0 (it) Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina.
TH58453B (th) การบำบัดของกรดไขมัน
SE8800101D0 (sv) Anvendning av essentiella fettsyror for framstellning av ett preparat for behandling av eksem
RU94008707A (ru) Готовые формы для снижения болезнетворного воздействия курения и способ применения их
SG115393G (en) The use of linoleic and alpha-linolenic acid metabolites for the preparation of pharmaceutical or dietary compositions for treatment of atopic disorders